Skip to main content
Media Hub

News

  • Corporate

    Protalix and Chiesi submit PRX-102 BLA for Fabry

    CARMIEL, Israel, May 28, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein…

  • Corporate

    Chiesi launches its Global Rare Diseases division

    Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities, with…

  • Corporate

    Chiesi acquires Ferriprox (deferiprone) from Apotex

    Chiesi Group expands distribution network via acquisition for worldwide product rights. Chiesi Group will establish offices in Toronto, Canada. PARMA, Italy, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group) and Apotex,…

  • Corporate

    Chiesi closes Santhera LHON licensing deal

    Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. As per the agreement, Chiesi Group is in-licensing a product whose active principle is idebenone for the treatment of Leber’s…

  • Corporate

    Chiesi wins the Imprese per Innovazione award

    Chiesi received the " Imprese per innovazione " award during the Connext event of February 6 and 7. Connext is the first National meeting of industry partnership organized by Confindustria, with the purpose of strengthening collaborations in the production area and in research and innovation…

  • Corporate

    Chiesi and TiumBio licence deal for respiratory drugs

    TiumBio grants Chiesi global rights to develop small molecules targeting transforming growth factor beta (TGF-β) signaling in respiratory indications This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical need Parma (Italy)- December 21, 2018 -…

  • Corporate

    StartUp Health raises $31M with the Chiesi Group

    StartUp Health announced a successful fundraise of 31 million dollars for its Transformer Fund II from a prominent consortium of strategic partners, including, as previously announced in June, the Chiesi Group. Other partners in this fund include large healthcare organizations, multinational large…

  • Corporate

    Chiesi's first digital health deal with StartUp Health

    Chiesi has signed a strategic deal with StartUp Health, a global health innovation company focused on achieving Health Moonshots. StartUp Health has the largest digital health-focused portfolio in the world, consisting of over 235 companies applying technology to solve key challenges such as…

  • Corporate

    Chiesi supports The Third Day exhibition in Parma

    From 20 April to 1 July 2018, the Governor’s Palace, in the heart of Parma’s historic centre, will host a unique exhibition, The Third Day, curated by Didi Bozzini and promoted by the Municipality of Parma. This series of events will provide the city with the opportunity to reflect on themes related…